IPW
NRXP icon

Impact Partnership Wealth’s NRX Pharmaceuticals NRXP Stock Holding History

Impact Partnership Wealth’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-94
Closed -$454 – 1141
2023
Q2 		$454 Buy
+94
New +$565 ﹤0.01% 865

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Impact Partnership Wealth's NRXP Position: Q3 2023 in Review

Impact Partnership Wealth sold out of NRX Pharmaceuticals (NRXP) in Q3 2023, closing a stake of 94 shares — an estimated $454 sold.

Impact Partnership Wealth first reported a position in NRXP in Q2 2023 and held it in 1 quarter. The position peaked at $454 in Q2 2023. 34 funds tracked by Wall St. Rank hold NRXP as of Q3 2023.

  • Impact Partnership Wealth reported no remaining NRX Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Impact Partnership Wealth sold 94 NRX Pharmaceuticals shares in Q3 2023, an estimated $454.
  • Impact Partnership Wealth first reported a position in NRX Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Impact Partnership Wealth's NRX Pharmaceuticals position peaked at $454 in Q2 2023.
  • 34 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2023.

Based on Impact Partnership Wealth's 13F filing for Q3 2023, filed 17 Oct 2023.